References
- Thomlinson RH, Gray LH. The histological structure of some human lung cancer and the possible implications for radiotherapy. Br J Cancer 1955; 9: 539–47.
- Kerr DJ, Kaye SB. Aspects of cytotoxic drug penetra-tion, with particular reference to anthracyclines. Cancer Chemother Pharmacol 1987; 9: 1–5.
- Simpson-Herren L, Noker PE. Diversity of penetration of anticancer agents into solid tumors. Cell Prolif 1991; 24: 355–65.
- Sutherland RM. Cell and environment interactions in tumour microregions. Science 1988; 240: 177–84.
- Mayer B, Klement G, Kaneko M et al. Multicellular gas-tric cancer spheroids recapitulate growth pattern and differen-tiation phenotype of human gastric carcinomas. Gastroenterology 2001; 121: 839–52.
- Sutherland RM, Eddy HA, Bareham B et al. Resistance to adriamycin in multicellular spheroids. Int J Radiat Oncol Biol Phys 1979; 5: 1225–30.
- Erlanson M, Daniel-Szolgay E, Carlsson J. Relation between the penetration, binding and average concentration of cytostatic drugs in human tumour spheroids. Cancer Chemoter Pharmacol 1992; 29: 343–53.
- Francia G, Man S, Teicher B et al. Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents. Mol Cell Biol 2004; 24: 6837–49.
- Gallois L, Fiallo M, Garnier-Suillerot A. Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles. Circular dichroism study. Biochim Biophys Acta 1998; 1370: 31–40.
- Berens ME, Saito T, Welander CE et al. Antitumour activity of new anthracycline analogues in combination with interferon alfa. Cancer Chemother Pharmacol 1987; 19: 301–6.
- Borchmann P, Hubel K, Schnell R et al. Idarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther 1997; 35: 80–3.
- Dodion P, Sanders C, Rombaut W, et al. Effect of daunorubicin, carminomycin, idarubicin and 4-demethoxy-daunorubicinol against human normal myeloid stem cells and human malignant cells in vitro. Eur J Cancer Clin Oncol 1987; 23: 1909-14.
- Glisson BS, Ross WE. DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol Ther 1987; 32: 69–106.
- Capranico G, Riva A, TineIli S et al. Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P338 leukemia cells and isolated nuclei. Cancer Res 1987; 47: 3752–6.
- Cairo MS, Toy C, Sender L et al. Effect of idarubicin and epirubicin on in vitro polymorphonuclear function: dimin-ished superoxide radical formation compared to their parent compounds daunorubicin and doxorubicin. J Leukoc Biol 1990; 47: 224–33.
- Kang W, Weiss M. Modeling the metabolism of idaru-bicin to idarubicinol in rat heart: effect of rutin and phenobar-bital. Drug Metab Dispos 2003; 31: 462–8.
- Bengala C, Danesi R, Guarneri V et al. High-dose con-solidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. Bone Marrow Transplant 2003; 31: 275–80.
- Toffoli G, Sorio R, Basso B et al. Pharmacokinetic comparison of 120-hour infusion versus hyperfractionated oral administration of idarubicin. J Chemother 2004; 16: 193–200.
- Yuhas JM, Li AP, Martinez AO et al. A simplified method for production and growth of multicellular tumor spheroids. Cancer Res 1977; 37: 3639–43.
- Chen FM, Liu CZ, Epstein AL. Effects of 131I-labeled TNT-1 radioimmunotherapy on HT-29 human colon adeno-carcinoma spheroids. Cancer Immunol Immunother 1991; 33: 158–64.
- Gewirtz DA, Randolph JK, Chawla J et al. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line. Cancer Chemother Pharmacol 1998; 41: 361–9.
- Ross DD, Doyle LA, Yang W et al. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance. Biochem Pharmacol 1995; 50: 1673–83.
- Ross DD, Gao Y, Yang W et al. The 95-kilodalton membrane glycoprotein overexpressed in novel multidrug-resistant breast cancer cells is NCA, the nonspecific cross-reacting antigen of carcinoembryonic antigen. Cancer Res 1997; 57: 5460–4.
- Roovers DJ, van Vliet M, Bloem AC et al. Idarubicin overcomes P-glycoprotein-related multidrug resistance: com-parison with doxorubicin and daunorubicin in human multiple myeloma cell lines. Leuk Res 1999; 23: 539–48.